Hikma Cuts $50M Deal To End Antitrust Claims In Xyrem MDL

By Dorothy Atkins · May 8, 2025, 6:30 PM EDT

A certified class of Xyrem buyers in 36 states have asked a California federal judge to preliminarily approve Hikma Pharmaceuticals PLC's $50 million deal to resolve antitrust claims accusing Hikma of...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Motion

Case Information

Case Title

In re Xyrem (Sodium Oxybate) Antitrust Litigation

Case Number

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

December 16, 2020

Recent Articles By Dorothy

May 16, 2025
Feds Want Ex-McKinsey Exec To Serve Time For Obstruction
April 22, 2025
Chase Bank Can't Ditch Claims It Aided $119M Ponzi Scam
March 12, 2025
Willkie Beats Malpractice Suit Over ERISA Ch. 11 Advice
February 28, 2025
FDIC Can't Nix SVB Trust's Claims Feds Must Turn Over $1.93B
January 22, 2025
Reed Smith Rips Claim Firm Is 'Causing Chaos' In $102M Suit
January 21, 2025
Ch. 11 Judge Slams Firm's 'Extraordinary' Lack Of Knowledge
December 12, 2024
BakerHostetler Can't Ditch RICO Claims In Bankruptcy Fight
August 30, 2024
5th Circ. Rejects SEC Whistleblower Award Calculation Appeal
August 29, 2024
Lannett Says Areva Reneged On Cancer-Drug Deal After Ch. 11
August 23, 2024
Split 9th Circ. Says Ponzi Schemes Don't Need Proof Of Intent